Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The miniscule carriers successfully transported and released live cells at a particular location within living mice.

As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together real-world results.  

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

Activating genes for reprogramming factors for a short time transforms large numbers of differentiated cells into multipotent forms that could be useful for cell-based therapies.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

A combination gene-and-cell therapy has given a boy with a grievous skin disease a new lease on life, and has resolved a dermatology debate to boot.

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

These engineered “cells” were made from the secretions and membranes of human mesenchymal stem cells.